Takeda Pharmaceutical

Update in progress

TAK (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Company Limited conducts research, development, manufacture, marketing, and out-licensing of medicines in Japan and worldwide. Its products cover gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Brands include Entyvio, Dexilant, Alunbrig, Velcade, Ninlaro, Adcetris, Vyvanse, and Exkivity, among others. It collaborates with multiple partners such as GSK, Halozyme, Kamada, and Seagen. Founded 1781, headquartered in Tokyo.

Company score

Sentiment: -0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.18; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.35; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -2.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.49; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.35; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive